Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FOENIX-CCA3: futibatinib versus gemcitabine + cisplatin in first-line FGFR2-rearranged advanced cholangiocarcinoma
jRCT2031200190Phase 3Active, not recruiting
- Sponsor
- Taiho Pharmaceutical Co., Ltd.
- Start
- Nov 2020
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, open-label trial of futibatinib, gemcitabine and cisplatin in cholangiocarcinoma (CCA) and intrahepatic cholangiocarcinoma (ICC) (2 arms), sponsored by Taiho Pharmaceutical Co., Ltd. Primary endpoint: Progression-free survival. Started Nov 2020; status: active, not recruiting.
02
Drugs
futibatinibgemcitabinecisplatin
03
Conditions
cholangiocarcinoma (CCA)intrahepatic cholangiocarcinoma (ICC)
Beyond the preview
Go deeper on jRCT2031200190.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031200190.